α-2b干扰素联合利巴韦林治疗丙型肝炎疗效分析

Efficacy of interferon alpha-2b combined with ribavirin on patients with hepatitis C

目的探讨α-2b干扰素治疗丙型肝炎的近期与远期疗效。方法给予急、慢性丙型肝炎患者α-2b干扰素5Mu肌肉注射,开始一个月每日1次,以后隔日1次,12个月为一个疗程;给予丙型肝炎肝硬化患者3Mu肌肉注射,隔日1次,治疗12个月。所有患者均联合应用利巴韦林,每日0.8～1.2g口服。随访2～5年。结果急性丙型肝炎患者在治疗结束时的应答率(ETR)为84.6%,稳定应答率(SR)为76.9%,慢性丙型肝炎ETR为61.4%,SR为52.3%(P<0.05);在5例丙型肝炎肝硬化患者,ETR为3例,SR2例;急慢性肝炎患者在治疗的最初1个月内应答者,其复发率低于1个月后才应答者(P<0.01)。结论α-2b干扰素治疗丙型肝炎的近期与远期疗效均较好,干扰素治疗的安全性较好,代偿期肝硬化患者也可抗病毒治疗。

Objective To assess the short-term and long-term efficacy of interferon alpha-2b in treating hepatitis C patients. Methods Acute and chronic hepatitis C patients were treated with interferon alpha-2b at 5Mu everyday for 1 month and every other day for 11 months,and the cirrhotics were treated with at 3Mu every other day for 12 months. All were treated with ribavirin at 800-1000mg/d for 12 months. Results The end treatment response （ETR） and steady response （SR） rates in acute hepatitis C patients were 84.6% and 76.9%,respectively. The ETR and SR rates in chronic hepatitis C patients were 61.4% and 52.3%,respectively （P〈0.05）;Three patients responded out of five cirrhosis patients; The patients with acute and/or chronic hepatitis C responding early in one month treatment relapsed less than those responding after one month（P〈0.01 ）. Conclusion The short-term and long-term efficacy of interferon alpha-2b in treating hepatitis C patients was fine. The steady response was higher in those responding early.